{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:02:27Z","timestamp":1788048147011,"version":"build-2784847793"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","award":["Roche Diagnostics"],"award-info":[{"award-number":["Roche Diagnostics"]}],"id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In this hypothesis-generating analysis, we examined whether longitudinal changes in patient-reported outcomes (PROs), such as symptoms, over time would be prognostic for progression-free survival (PFS) and overall survival (OS) in patients with diffuse large B-cell lymphoma (DLBCL) who were newly treated with obinutuzumab (G) in combination with CHOP (G-CHOP) or rituximab (R) with CHOP (R-CHOP), in the GOYA Phase 3 trial (NCT01287741). Our results show that from the study baseline to cycle 3\u00a0day 1, every 1-point increase (worsening) in fever symptoms was associated with a 41% higher risk of death (hazard ratio [HR], 1.41;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01). Every 1-point increase (worsening) in lumps or swelling symptoms was associated with a 27% higher risk of disease progression or death (PFS events) (HR, 1.27;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01) and a 29% higher risk of death (OS events) (HR, 1.29;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02). No significant associations were observed between survival and changes in other symptoms, such as itching. Our study suggests that changes in some PROs are related to survival in DLBCL patients.\n                  <\/jats:p>","DOI":"10.1186\/s41687-024-00708-w","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T04:02:25Z","timestamp":1710734545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Are changes in patient-reported outcomes prognostic for diffuse large B-Cell lymphoma survival? Results from the GOYA trial"],"prefix":"10.1186","volume":"8","author":[{"given":"Jessie T.","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Trask","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"708_CR1","unstructured":"Lymphoma Research Foundation, Lymphoma DLB-C (2021) https:\/\/lymphoma.org\/understanding-lymphoma\/aboutlymphoma\/nhl\/dlbcl\/. (Accessed November 18, 2022)"},{"key":"708_CR2","unstructured":"National Cancer Institute, SEER Cancer Stat Facts (2022) Diffuse Large B-Cell Lymphoma. https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html"},{"key":"708_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1477-7525-7-102","volume":"7","author":"A Montazeri","year":"2009","unstructured":"Montazeri A (2009) Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 7:102. https:\/\/doi.org\/10.1186\/1477-7525-7-102","journal-title":"Health Qual Life Outcomes"},{"issue":"17","key":"708_CR4","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1002\/cam4.4692","volume":"11","author":"H Huang","year":"2022","unstructured":"Huang H, Datye A, Fan M, Knapp A, Nielsen T, Bottos A, Paulson JN, Trask PC, Efficace F (2022) Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: analysis of 1239 patients from the GOYA study. Cancer Med 11(17):3312\u20133322. https:\/\/doi.org\/10.1002\/cam4.4692","journal-title":"Cancer Med"},{"issue":"31","key":"708_CR5","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trneny M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH (2017) Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in previously untreated diffuse large B-Cell lymphoma. J Clin Oncol 35(31):3529\u20133537. https:\/\/doi.org\/10.1200\/JCO.2017.73.3402","journal-title":"J Clin Oncol"},{"issue":"5","key":"708_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"J Natl Cancer Inst"},{"key":"708_CR7","volume-title":"EORTC QLQ-C30 Scoring Manual","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 Scoring Manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels","edition":"3"},{"issue":"11","key":"708_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1182\/blood.V106.11.750.750","volume":"106","author":"D Cella","year":"2005","unstructured":"Cella D, Webster K, Cashy J, Kutikova L, Burgess MF, Lin BK, Bowman L, Liepa AM, Gauthier JE, Gregory SA, Johnson SA, Cheson BD, on Behalf of the FACT-Lym Development Group (2005) Development of a measure of Health-Related Quality of Life for Non-hodgkin\u2019s Lymphoma Clinical Research: the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym). Blood 106(11):750\u2013750. https:\/\/doi.org\/10.1182\/blood.V106.11.750.750","journal-title":"Blood"},{"key":"708_CR9","unstructured":"FACIT group, FACT-Lym Functional Assessment of Cancer Therapy\u2013 Lymphoma For patients with Lymphoma (NHL) (2021) https:\/\/www.facit.org\/measures\/FACT-Lym. (Accessed October 28, 2002)"},{"issue":"1","key":"708_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139\u2013144. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.139","journal-title":"J Clin Oncol"},{"issue":"11","key":"708_CR11","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1182\/blood.V112.11.2376.2376","volume":"112","author":"GC Carter","year":"2008","unstructured":"Carter GC, Liepa AM, Zimmermann AH, Morschhauser F (2008) Validation of the Functional Assessment of Cancer therapy\u2013lymphoma (FACT-LYM) in patients with Relapsed\/Refractory Mantle Cell Lymphoma. Blood 112(11):2376\u20132376. https:\/\/doi.org\/10.1182\/blood.V112.11.2376.2376","journal-title":"Blood"},{"issue":"1\u20133","key":"708_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.schres.2010.01.021","volume":"118","author":"MK Vernon","year":"2010","unstructured":"Vernon MK, Revicki DA, Awad AG, Dirani R, Panish J, Canuso CM, Grinspan A, Mannix S, Kalali AH (2010) Psychometric evaluation of the medication satisfaction questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res 118(1\u20133):271\u2013278. https:\/\/doi.org\/10.1016\/j.schres.2010.01.021","journal-title":"Schizophr Res"},{"issue":"2","key":"708_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102\u2013109. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.012","journal-title":"J Clin Epidemiol"},{"key":"708_CR14","unstructured":"Leukemia (2023) Accessed June 14, & Lymphoma Society, Signs and Symptoms. https:\/\/www.lls.org\/lymphoma\/non-hodgkin-lymphoma\/signs-and-symptoms"},{"issue":"4","key":"708_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.18043\/ncm.75.4.283","volume":"75","author":"MJ Naughton","year":"2014","unstructured":"Naughton MJ, Weaver KE (2014) Physical and mental health among cancer survivors: considerations for long-term care and quality of life. N C Med J 75(4):283\u2013286. https:\/\/doi.org\/10.18043\/ncm.75.4.283","journal-title":"N C Med J"},{"issue":"8","key":"708_CR16","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jval.2011.06.003","volume":"14","author":"S Rolstad","year":"2011","unstructured":"Rolstad S, Adler J, Ryden A (2011) Response burden and questionnaire length: is shorter better? A review and meta-analysis. Value Health 14(8):1101\u20131108. https:\/\/doi.org\/10.1016\/j.jval.2011.06.003","journal-title":"Value Health"},{"issue":"2","key":"708_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.rmed.2006.04.023","volume":"101","author":"MA Puhan","year":"2007","unstructured":"Puhan MA, Guyatt GH, Goldstein R, Mador J, McKim D, Stahl E, Griffith L, Schunemann HJ (2007) Relative responsiveness of the chronic respiratory questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respir Med 101(2):308\u2013316. https:\/\/doi.org\/10.1016\/j.rmed.2006.04.023","journal-title":"Respir Med"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00708-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T04:02:30Z","timestamp":1710734550000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00708-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00708-w","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The GOYA study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines for Good Clinical Practice (GCP). The protocol was approved by the ethics committees of participating centers and registered at ClinicalTrials.gov (NCT01287741;\n                      \n                      ). All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JTY, and EL are employees of Roche Diagnostics, Santa Clara, and hold Roche stocks; PCT is an employee of Genentech Inc. and holds Roche stocks; CB is an employee of F. Hoffmann-La Roche Ltd, Diagnostics Division, Basel, Switzerland.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}